Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Darren Carpizo
Rbhs Cancer Institute of New Jersey, Department: None
Should you be removed from our database? Contact us at [email protected]. Read more below.
Z53 Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The subject matter of the research project is identical to the focus of the company. Moreover, Dr. Carpizo is one of the founders of Z53 Therapeutics. There is a research agreement, as wells, a licensing agreement in place between Rutgers and Z53 Therapeutics
Development of Zinc Metallochaperones as Mutant p53 Targeted Anti-cancer Drugs
We have discovered a new class of drugs called Zinc Metallochaperones that targets the most commonly mutated gene in cancer, TP53. By restoring the function of p53 in tumors, these drugs have the potential to extend the lives of more than 75,000 new cancer patients yearly. Because of the frequency of mutations in p53, these drugs will benefit patients with all types of cancers.
Filed on July 19, 2016.
Tell us what you know about Darren Carpizo's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Darren Carpizo filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Darren Carpizo | Rbhs Cancer Institute of New Jersey | Conflict of Interest | Z53 Therapeutics | $40,000 - $59,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.